nkgenbiotech.com (NKGN) - Uzoq muddatli majburiyatlarning kapitalga nisbati

NKGen Biotech, Inc. (NKGN) onkologiya va Altsgeymer kasalligi uchun innovatsion davolash usullarini ishlab chiqmoqda va ilg'or tibbiyot sohasidagi o'z mavqeini kengaytirmoqda. Biroq, har bir bemor uchun hujayralarni qo'lda yetishtirishning murakkabligi o'sishni cheklaydi, bu esa ommaviy ishlab chiqarish imkoniyatini yo'qqa chiqaradi. Joriy ko'rsatkich 0.00 darajasida turibdi, biznes esa kapitalni sinovlar uchun sarflagan holda, foydasiz ishlamoqda. Narxlar dinamikasini aks ettiruvchi ushbu kunlik narxlar grafigi operatsion impulsning yetishmasligini tasdiqlaydi.

NKGen Biotech Inc (NKGN): Uzoq muddatli qarzning o'z kapitaliga nisbati 21.02.2024dan 15.03.2025gacha

NKGen Biotech, Inc. kompaniyasining tahliliy kesimlari

- joriy narx va aksiyalarning prognoz qilingan qiymati:
Aksiya kursi NKGen Biotech Inc|NKGN - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor qiymati NKGen Biotech, Inc.|NKGN - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- xususiy kapitalning balans qiymati ko'rsatkichlari:
Bitta aksiya hisobiga balans qiymati NKGen Biotech|NKGN - Kompaniyaning balans qiymati|Balans qiymatiga nisbatan bozor qiymati nkgenbiotech.com|NKGN - Kompaniyaning jami aktivlari
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning kapitalga nisbati NKGen Biotech, Inc.|NKGN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi nkgenbiotech.com|NKGN - Kompaniya qarzlari|Balans kapitallashuviga qarzlar NKGen Biotech, Inc.|NKGN - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarzdorlik NKGen Biotech|Shoshilinch likvidlik nkgenbiotech.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
NKGN - Kompaniyaning sof foydasi
Kompaniyaning har tomonlama tahlili:NKGN, NKGen Biotech Inc

Uzoq muddatli qarzdorlikning kapitalga nisbati umumiy kapital tuzilmasida muddati bir yildan ortiq bo'lgan qarzlarning ulushini o'lchaydi. Ushbu metrika moliyaviy leverajni o'lchab, qarz yuklamasi va moliyaviy barqarorlik o'rtasidagi muvozanatni namoyish etadi. Uzoq muddatli qarzdorlikning kapitalga nisbatining joriy darajasini tahlil qilish orqali investorlar bankrotlik xatarlarini va qarz olish xarajatlarini boshqarish samaradorligini baholaydilar. NKGen Biotech uchun ushbu metrika kompaniyaning haddan tashqari leverajsiz hujayra materiallarining murakkab xalqaro logistikasini moliyalashtirish qobiliyatini aks ettiradi. Ushbu nisbatni optimallashtirish kompaniyaga xomashyolarni laboratoriyalarga tashishda yuqori marjalarni saqlab qolish imkonini beradi.

Muhim raqobatchilar

Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi BIIB (Biogen Inc)|Uzoq muddatli qarzning kapitalga nisbati NBIX|RGC - Uzoq muddatli majburiyatlarning kapitalga nisbati|Axsome Therapeutics - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati acadia-pharm.com ACAD|XENE - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti VKTX (Viking Therapeutics Inc)|Supernus Pharma (SUPN) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Catalyst Corp (CPRX)|Uzoq muddatli qarzning o'z kapitaliga nisbati Denali Therapeutics|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi HRMY (harmonybiosciences.com)|Uzoq muddatli qarzning o'z kapitaliga nisbati Biohaven (BHVN)|Uzoq muddatli qarzning kapitalga nisbati Amylyx Pharmaceuticals Inc (AMLX)|Uzoq muddatli qarzning kapitalga nisbati TRVI (Trevi Pharma)|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Praxis Corp|Anavex Life Sciences - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati ceribell.com|Prothena Corp (PRTA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi ALEC|Uzoq muddatli qarzning o'z kapitaliga nisbati ANNX|OMER: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati NGNE|Uzoq muddatli qarzning o'z kapitaliga nisbati ACIU (acimmune.com)|Uzoq muddatli qarzning kapitalga nisbati VYGR (Voyager Therapeutics, Inc.)|Uzoq muddatli qarzdorlikning kapitalga nisbati Neumora (NMRA)|SCLX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Tevogen Bio Inc.|ACOG (alphacognition.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|CGTX: Uzoq muddatli kreditlarning kapitalga nisbati|IKT (Inhibikase Therapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Cassava Sciences Inc SAVA|Uzoq muddatli qarzning kapitalga nisbati ASRT|Uzoq muddatli qarzning o'z kapitaliga nisbati coyatherapeutics.com COYA|Uzoq muddatli qarzning kapitalga nisbati VTGN (Vistagen)|Uzoq muddatli qarzning kapitalga koeffitsiyenti OVID|ABOS: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti CRVO (CervoMed, Inc.)|ATHE: Uzoq muddatli qarzning kapitalga nisbati|CLNN - Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati PepGen Inc|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi JUNS (jupiterneurosciences.com)|Uzoq muddatli qarzning kapitalga nisbati RLMD|Uzoq muddatli qarzning o'z kapitaliga nisbati Annovis Bio Inc ANVS|Grace Therapeutics - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Firefly Neuro (AIFF)|KLTO - Uzoq muddatli qarzning o'z kapitaliga nisbati|NRSN (NeuroSense Therapeutics) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Uzoq muddatli qarzning o'z kapitaliga nisbati|MetaVia (MTVA) - Uzoq muddatli qarzning kapitalga nisbati|NRXS (NeurAxis, Inc) - Uzoq muddatli qarzning kapitalga nisbati|HSDT - Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Passage Bio, Inc. (PASG)|bionomics.com.au - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Uzoq muddatli qarzning o'z kapitaliga nisbati Minerva Neurosciences, Inc. NERV|ATHA: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Addex Therapeutics, Ltd. - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Protagenic Therapeutics, Inc. (PTIX) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Pasithea Therapeutics Corp|CRGT: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati Avenue Therapeutics, Inc (ATXI)|BCLI - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Cara Therapeutics, Inc. CARA|CHRO: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|ELYM - Uzoq muddatli qarzning o'z kapitaliga nisbati|ITCI - Uzoq muddatli qarzning kapitalga nisbati|LBPH: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Marinus Pharma MRNS|NRBO (NeuroBo Pharmaceuticals) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati sagerx.com SAGE|Uzoq muddatli qarzning o'z kapitaliga nisbati Synaptogenix (SNPX)|Trevena Inc. - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Vigil Neuroscience, Inc. - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti WENA|Cerevel Therapeutics - Uzoq muddatli qarzning kapitalga nisbati